Compare Stocks → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADVMNASDAQ:HARPNASDAQ:PRVLNASDAQ:REPLNASDAQ:TCRR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$9.39-7.9%$15.62$7.10▼$29.70$194.84M0.84249,470 shs838,744 shsHARPHarpoon Therapeutics$23.01$22.89$3.11▼$23.21$389.61M2.111.52 million shsN/APRVLPrevail Therapeutics$23.00$23.01$9.02▼$23.35$787.66M1.59955,800 shsN/AREPLReplimune Group$6.15-2.8%$7.86$5.86▼$24.81$377.54M1.211.33 million shs783,453 shsTCRRTCR2 Therapeutics$1.48-5.7%$1.65$0.82▼$3.88$58.11M1.95494,777 shs3.91 million shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies-7.36%-10.22%-31.84%+13.85%+23.95%HARPHarpoon Therapeutics0.00%0.00%0.00%+2.72%+302.98%PRVLPrevail Therapeutics0.00%0.00%0.00%0.00%0.00%REPLReplimune Group-1.40%-12.21%-21.37%-19.77%-63.60%TCRRTCR2 Therapeutics0.00%0.00%0.00%0.00%-16.38%Thousands of investors use this no cost solution | Do you? (Ad)In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage"MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVMAdverum Biotechnologies3.7869 of 5 stars3.51.00.04.82.42.50.0HARPHarpoon Therapeutics1.9155 of 5 stars2.20.00.04.72.04.20.0PRVLPrevail TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AREPLReplimune Group4.4946 of 5 stars3.51.00.04.53.73.31.3TCRRTCR2 TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies3.00Buy$34.67269.19% UpsideHARPHarpoon Therapeutics2.33Hold$27.2518.43% UpsidePRVLPrevail TherapeuticsN/AN/AN/AN/AREPLReplimune Group3.00Buy$37.67512.47% UpsideTCRRTCR2 TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest ADVM, HARP, TCRR, PRVL, and REPL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2024HARPHarpoon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/19/2024ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.002/26/2024HARPHarpoon TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$13.00 ➝ $23.002/6/2024ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $40.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$3.60M54.12N/AN/A$8.26 per share1.14HARPHarpoon Therapeutics$37.34M10.43N/AN/A$1.63 per share14.12PRVLPrevail TherapeuticsN/AN/AN/AN/A$4.85 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$9.80 per shareN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/A$2.58 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$117.17M-$11.60N/AN/AN/AN/A-98.65%-52.85%5/9/2024 (Estimated)HARPHarpoon Therapeutics-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/APRVLPrevail Therapeutics-$63.19M-$2.22N/AN/AN/AN/A-55.57%-48.14%N/AREPLReplimune Group-$174.28M-$3.16N/AN/AN/AN/A-42.94%-35.80%5/16/2024 (Estimated)TCRRTCR2 Therapeutics-$151.82M-$4.20N/AN/AN/AN/A-97.81%-69.35%N/ALatest ADVM, HARP, TCRR, PRVL, and REPL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023ADVMAdverum Biotechnologies-$2.80-$2.30+$0.50-$2.30N/AN/A2/8/2024Q3 2024REPLReplimune Group-$0.89-$0.77+$0.12-$0.77N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AHARPHarpoon TherapeuticsN/AN/AN/AN/AN/APRVLPrevail TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A4.134.13HARPHarpoon TherapeuticsN/A1.891.89PRVLPrevail TherapeuticsN/A7.567.56REPLReplimune Group0.1612.4012.40TCRRTCR2 TherapeuticsN/A2.962.96OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%HARPHarpoon Therapeutics74.01%PRVLPrevail Therapeutics86.80%REPLReplimune Group92.53%TCRRTCR2 Therapeutics64.76%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies5.30%HARPHarpoon Therapeutics17.00%PRVLPrevail Therapeutics57.20%REPLReplimune Group20.60%TCRRTCR2 Therapeutics25.01%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies12120.75 million19.66 millionOptionableHARPHarpoon Therapeutics5316.93 million14.05 millionOptionablePRVLPrevail Therapeutics6634.25 millionN/ANot OptionableREPLReplimune Group28461.39 million48.74 millionOptionableTCRRTCR2 Therapeutics13739.26 million29.44 millionNot OptionableADVM, HARP, TCRR, PRVL, and REPL HeadlinesSourceHeadlineTCR2 Therapeutics gets grant for recombinant nucleic acid encoding TCR fusion protein for cancer treatmentpharmaceutical-technology.com - April 17 at 9:14 AMPoseida Therapeutics Inc Ordinary Shares PSTXmorningstar.com - February 25 at 9:43 AMDICE Therapeutics Inc.wsj.com - June 20 at 11:13 PMAdaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Companyfinance.yahoo.com - June 1 at 4:46 PMTCR2 Therapeutics Insider Trades Send a Signalbenzinga.com - May 16 at 1:36 PMRecap: TCR2 Therapeutics Q1 Earningsmsn.com - May 12 at 9:26 AM10-Q: TCR2 THERAPEUTICS INC.marketwatch.com - May 11 at 11:15 PMTCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 11 at 8:13 AMCompanies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite Riskyfinance.yahoo.com - April 15 at 12:05 PMMizuho Downgrades Tcr2 Therapeutics (TCRR)msn.com - March 25 at 7:55 PMTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho Securitiesmarkets.businessinsider.com - March 23 at 7:23 PMAnalysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)markets.businessinsider.com - March 23 at 2:23 PMTCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 23 at 9:22 AMTCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - March 23 at 9:22 AMWhat To Know About Jefferies's Downgrade of TCR2 Therapeuticsmsn.com - March 9 at 5:14 PM4 Analysts Have This to Say About TCR2 Therapeuticsmarkets.businessinsider.com - March 9 at 12:14 PMTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. Wainwrightmarkets.businessinsider.com - March 8 at 8:52 PMShareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmunebenzinga.com - March 6 at 7:17 PMSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. Buyoutbenzinga.com - March 6 at 7:17 PMWhy Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?investorplace.com - March 6 at 12:02 PMTCR2 Therapeutics: Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumorsfinanznachrichten.de - March 6 at 8:28 AMAdaptimmune To Combine With TCR² In All-stock Deal - Quick Factsmarkets.businessinsider.com - March 6 at 8:28 AMAdaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumorsfinance.yahoo.com - March 6 at 8:28 AMAdaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumorsfinance.yahoo.com - March 6 at 8:28 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinksApril 25, 2024 2:14 AMView Stock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinksFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentGE Aerospace is Ready for Liftoff After Strong EarningsApril 24, 2024 9:07 AMView GE Aerospace is Ready for Liftoff After Strong EarningsBuy the Dip in Paychex, Inc. for a Pay Check at RetirementApril 2, 2024 11:07 AMView Buy the Dip in Paychex, Inc. for a Pay Check at RetirementAll Headlines Company DescriptionsAdverum BiotechnologiesNASDAQ:ADVMAdverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Harpoon TherapeuticsNASDAQ:HARPHarpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.Prevail TherapeuticsNASDAQ:PRVLPrevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.Replimune GroupNASDAQ:REPLReplimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.TCR2 TherapeuticsNASDAQ:TCRRTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.